ReviewCureus2025
Enoxaparin Versus Dalteparin for Venous Thromboembolism Prophylaxis in Hip and Knee Arthroplasty: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a serious postoperative complication in patients undergoing total hip or knee arthroplasty, with both pulmonary embolisms and deep vein thromboses being major causes of preventable morbidity and mortality. Low-molecular-weight heparins such as enoxaparin and dalteparin are widely used for thromboprophylaxis, but direct comparative data are limited. We aimed to do a systematic review of the literature to compare the efficacy and safety of enoxaparin and dalteparin in preventing VTE following total hip or knee replacement surgery. A systematic literature search was conducted in MEDLINE, PubMed, Embase, and the Cochrane Library. After deduplication, 145 studies were screened, 28 full texts were assessed, and three papers were included. Eligible studies were randomised controlled trials (RCTs) or observational studies comparing enoxaparin and dalteparin in adult patients undergoing hip or knee arthroplasty, reporting VTE rates as the primary outcome. Risk of bias (ROB) was assessed using the Cochrane RoB 2 tool for randomised trials and the Newcastle-Ottawa Scale for observational studies. Three studies - one RCT and two retrospective cohort studies with a total of 1,167 patients - met the inclusion criteria. Across all studies, VTE incidence was low with no significant difference between enoxaparin and dalteparin. Some evidence suggested dalteparin may be associated with fewer bleeding events and lower transfusion rates, with one study also reporting cost savings. ROB was moderate in the observational studies, with some concerns in the RCTs. Enoxaparin and dalteparin appear similarly effective for VTE prevention after hip or knee arthroplasty. However, dalteparin may be associated with a lower bleeding risk and reduced transfusion rates, with potential cost savings. Current evidence is limited by the small number and quality of studies. Further high-quality randomised trials are needed to confirm these findings and inform clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.